Targeted therapy for triple-negative breast cancer

Targeted therapies, a type of systemicinfo-icon cancer treatment, work by targeting features, called biomarkers, that are needed for cancer cells to survive and grow. Until recently, chemotherapyinfo-icon was the only systemic treatment option for triple-negative breast cancerinfo-icon, and it continues to be the most effective treatment for many people.

This is because triple-negative breast cancers are not fueled by estrogeninfo-icon or progesteroneinfo-icon and do not have receptors for the HER2 proteininfo-icon, targets that guided some of the first breast cancer targeted therapies. But new treatments have become available that target biomarkers found in some triple-negative breast cancers.

In this section, you’ll learn more about the different classes of targeted therapies for triple-negative breast cancer, the biomarkers that tell us who may benefit from them, and how they work.

Updated 
January 4, 2021
Reviewed By: